Form 4: Neurocrine CEO Exercises, Sells NBIX Stock Options

Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold 36,400 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Kyle Gano, Chief Executive Officer and Director of Neurocrine Biosciences Inc. (NBIX), executed transactions on January 16, 2026, involving the exercise of stock options and the subsequent sale of common stock.
• Gano exercised Non-Qualified Stock Options for 34,588 shares and Incentive Stock Options for 1,812 shares, totaling 36,400 shares, all at an exercise price of $35.99 per share.
• Concurrently, 34,588 shares were sold at a weighted average price of $132.7044 per share, with individual sales prices ranging from $131.42 to $133.98.
• An additional 1,812 shares were sold at a weighted average price of $132.7143 per share, with individual sales prices ranging from $131.49 to $133.79.
• These dispositions were made pursuant to a Rule 10b5-1 trading plan adopted by Gano on May 20, 2025.
• Following these transactions, Gano's direct beneficial ownership of common stock is 140,407 shares.
• The options were granted on February 5, 2016, vested in 48 equal monthly installments beginning on March 5, 2016, and were due to expire on February 5, 2026.

Sentiment

Score: 5

Explanation: The transaction is a routine exercise and sale of stock options by the CEO under a pre-arranged 10b5-1 plan, which is a common executive compensation event and does not inherently signal strong positive or negative sentiment about the company's future.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which enhances transparency and mitigates concerns about opportunistic insider trading.
• The CEO is realizing value from previously granted stock options, indicating past performance and vesting of long-term incentives.

Negatives

• The CEO sold a significant number of shares (36,400), which, while pre-planned, represents a reduction in direct equity holdings.

Future Outlook

This filing, a Form 4, primarily reports insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The disposition reported was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025.
• Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Industry Context

This transaction represents a routine executive compensation event, common in the biotechnology and pharmaceutical industries, where executives exercise vested stock options and sell shares for diversification or liquidity purposes. The use of a Rule 10b5-1 plan is standard practice to manage such transactions in compliance with insider trading regulations.

Comparison to Industry Standards

• The exercise and sale of stock options by a CEO is a standard component of executive compensation packages across various industries, including biotech.
• The execution of these transactions under a Rule 10b5-1 trading plan aligns with best practices for corporate governance, similar to how executives at comparable companies manage their equity holdings to avoid perceptions of opportunistic trading.

Corporate Governance

Stakeholder Impact

• Shareholders may note the CEO's sale of shares, but the pre-arranged 10b5-1 plan mitigates concerns about the timing or intent of the sale.
• The transaction is a routine part of executive compensation, impacting the CEO's personal financial planning and diversification.

Next Steps

• The options exercised were due to expire on February 5, 2026, indicating a timely exercise before expiration.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled exercise of stock options and subsequent sale of shares by the CEO under a Rule 10b5-1 trading plan. Such transactions are common for executive compensation and diversification and typically do not indicate a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

Neurocrine Biosciences, NBIX, Kyle Gano, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, CEO, Stock Sale, Equity Transaction, Executive Compensation